---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000197"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:33:21.568318+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# USANA Q4 net sales $228M (-15% YoY), EPS $0.66 (-36%); FY2023 guidance reiterated

## Summary
- Q4 net sales $228M, down 15% YoY; diluted EPS $0.66, down 36% YoY.
- FY2022 net sales $999M (-16% YoY), EPS $3.59 (-37%); operating cash flow $104M.
- Active customers 490,000, down 13% YoY but up 3% sequentially; key markets stabilized.
- FY2023 outlook: net sales $850M-$950M, diluted EPS $2.35-$3.30; wide range on China uncertainty.
- Ended with $288M cash, debt-free; $83M share buyback remaining; no Q4 repurchases.

## SEC filing metadata
- accession: 0001157523-23-000197
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/a53305227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000197
- JSON: https://secwatch.observer/filing/0001157523-23-000197.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000197.txt

## Key facts
- Earnings Releases
  USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $850 million to $950 million, EPS $2.35 to $3.30. Guidance reaffirmed.
  - Period: fiscal year 2023
  - Revenue: $850 million to $950 million
  - EPS: $2.35 to $3.30
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm
- Earnings Releases
  USANA HEALTH SCIENCES INC reported fiscal year ended December 31, 2022 results: revenue $999 million, EPS $3.59. Guidance reaffirmed.
  - Period: fiscal year ended December 31, 2022
  - Revenue: $999 million
  - EPS: $3.59
  - Guidance: reaffirmed
  - Result: reported results
  source text: Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm
- Earnings Releases
  USANA HEALTH SCIENCES INC reported fourth quarter ended December 31, 2022 results: revenue $228 million, EPS $0.66. Guidance reaffirmed.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $228 million
  - EPS: $0.66
  - Guidance: reaffirmed
  - Result: reported results
  source text: Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.